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Abstract 
Severe asthma (SA) is a clinically and etiologically heterogeneous respiratory disease which affects among 5–10 % of 
asthmatic patients. Despite high-dose therapy, a large patients percentage is not fully controlled and has a poor qual-
ity of life. In this review, we describe the biomarkers actually known in scientific literature and used in clinical practice 
for SA assessment and management: neutrophils, eosinophils, periostin, fractional exhaled nitric oxide, exhaled breath 
condensate and galectins. Moreover, we give an overview on clinical and biological features characterizing severe 
asthma, paying special attention to the potential use of these ones as reliable markers. We finally underline the need 
to define different biomarkers panels to select patients affected by severe asthma for specific and personalized thera-
peutic approach.
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Background
Severe asthma (SA) is defined as ‘asthma which requires 
treatment with high dose inhaled corticosteroids (ICS) 
plus a second controller (and/or systemic corticoster-
oids) to prevent it from becoming ‘uncontrolled’ or which 
remains ‘uncontrolled’ despite this therapy’. This is the 
European Respiratory Society (ERS)/American Thoracic 
Society (ATS) definition, utilized across developed coun-
tries with general access to inhaled corticosteroid therapy 
[1, 2]. It is recognized that up to 50 % of patients are not 
well controlled and 5–10 % of patients suffer from a par-
ticularly severe disease that is often refractory to usual 
treatment [3, 4].
Evidence of any one of the four criteria below, while on 
current high-dose therapy, identifies the patient as having 
‘‘severe asthma’’:
1. Poor symptoms control.
2. Frequent severe exacerbations, defined as two or 
more bursts of systemic corticosteroids in the previ-
ous year.
3. Serious exacerbations, defined as at least one hospi-
talization, intensive care unit stay or mechanical ven-
tilation in the previous year.
4. Airflow limitation, i.e. forced expiratory volume in 1 s 
(FEV1), 80  % predicted (in the presence of reduced 
FEV1/forced vital capacity (FVC) defined as less than 
the lower limit of normal) following a withhold of 
both short- and long-acting bronchodilators.
Asthma, and severe asthma in particular, are increas-
ingly considered as heterogeneous diseases, which may 
respond similarly to therapies. Recently, studies are 
beginning to identify different phenotypes defined by 
characteristic clinical manifestations, pathophysiological 
mechanisms and biomarkers [5].
The first studies performed in asthmatics distinguished 
subtypes based on inflammatory patterns obtained 
from bronchoalveolar lavage and endobronchial biop-
sies. Identifying patients with corticosteroid-naive, mild 
asthma who exhibited a T-helper (Th)2/Type 2 molecular 
signature in their epithelial cells, Woodruff et al., began 
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the concept of molecular phenotyping, in which molecu-
lar pathways are linked to clinical and physiological char-
acteristics [6].
A more detailed immunopathobiological picture of 
human SA is therefore emerging as the context of the 
heterogeneity of the disease, in relation to both inflam-
mation and structural changes [7].
The identification of asthma phenotypes has given 
a boost to the search for biomarkers to help classify-
ing patients, targeting therapies and predicting different 
pathological evolution mechanisms of the disease with 
strong benefits for the affected patients [8].
An ideal biomarker is easy to collect and measure, not 
invasive nor expensive, and can be used to identify either 
clinical or treatment response phenotypes, evaluate 
changes in disease activity, or confirm a diagnosis. This 
prospect provides the impetus for the research for relia-
ble markers in SA, which are actually under intense study 
and are hereunder analyzed. In this review we focus the 
importance and the role of different known and potential 
biomarkers useful to define the physiopathological and 
clinical profiles of patients affected by severe asthma.
Neutrophils
Severe asthma is often characterized by neutrophilic 
inflammation, both in the presence or absence of Th2-
induced eosinophilic inflammation [9, 10]. However, 
the functional role of these cells in disease progression 
remains unclear. Sputum neutrophil percentages are 
highly reproducible in patients with moderate to severe 
asthma, and can be used to assess novel anti-inflamma-
tory therapies: targeting neutrophils has been suggested 
as a therapeutic option for these patients [11, 12].
Neutrophils recruitment can be mediated by Th17 cells, 
which are thought to have a role in asthma pathogenesis, 
especially in patients who do not respond to glucocorti-
coid therapy and show a decreased improvement in FEV1 
and airway hyperresponsiveness (AHR) following treat-
ment [13, 14]. Moreover, it has been demonstrated that, 
in addition to the specific antigenic components, pollens 
contain several intrinsic factors able to promote innate 
immune responses; among them, nicotinamide adenine 
dinucleotide phosphate oxidase (NADPH) induces the 
generation of reactive oxygen species (ROS) [15]. This 
oxidative insult induces an early wave of neutrophil 
recruitment in the airways and increases significantly 
ROS-generating activity of these cells [16]. It has been 
also evidenced that pollen can induce CXCL chemokine 
synthesis and that neutrophils can be recruited into the 
airways in a CXCR2-dependent manner [17].
The receptor for advanced glycation end-products 
(RAGE) is a pattern recognition receptor involved in 
the response to injury, infection and inflammation. 
Perturbations in the RAGE and its soluble forms (sRAGE) 
balance might be linked to neutrophilic airway inflam-
mation in chronic airways disease [18]. A recent work 
from Sukkar et al. demonstrated a deficiency in lung and 
systemic sRAGE, in asthmatic and chronic obstructive 
pulmonary disease (COPD) patients with neutrophilic 
airway inflammation. sRAGE might be degraded by 
neutrophil-derived proteolytic enzymes in subjects with 
airway neutrophilia and might be identified as a potential 
biomarker for prognosis or patient management [19].
The metalloproteinase domain 8 (ADAM8) seems also 
to be involved in facilitating neutrophils migration into 
tissues [20]. It is highly expressed in bronchial biopsies 
from moderate and severe asthmatics and its recruitment 
of both eosinophils and neutrophils into airways tissue 
suggests a significant role in the pathogenesis of asthma 
[21–24].
Future therapeutic targets directed at the above men-
tioned proteins might significantly attenuate asthma 
symptoms by reducing inflammatory cells, primar-
ily neutrophils, and having few adverse physiological 
consequences.
Eosinophils
Asthma is also histologically characterized by recruit-
ment of eosinophils into the large airway wall and lumen, 
along with mucus plugging and epithelium denudation. 
Being associated with increased transforming growth 
factor β (TGF-β) expression and reticular basement 
membrane (RBM) thickness, the amount of these cells 
might be congruent with symptoms severity, worsened 
lung function, and near-fatal events [25–27].
The identification of eosinophilic inflammation is of a 
certain importance due to the severity of attacks which 
occur to these patients and to the existence of drugs, 
such as prednisolone, omalizumab and new biological 
agents, particularly active on this pattern [28].
It is known that Type-2 inflammatory pathways are 
involved in asthma, and many studies suggest that 
about 50  % of SA patients present Type-2 inflamma-
tion, as measured by eosinophilia or high levels of frac-
tional exhaled nitric oxide (FeNO) [29, 30]. Miranda 
et  al. distinguished early-onset severe asthma patients, 
characterized by allergen sensitivity, allergic symptoms, 
eosinophilia and higher serum immunoglobulin E (IgE) 
levels, and late-onset severe asthma subjects, with lower 
lung function than early-onset ones, despite a shorter 
duration of illness and significantly more symptoms if 
presenting persistent eosinophils at onset [27].
The need to block IgE binding to inflammatory cells 
and the consequent mediators release cascade con-
curred to the development of the unique monoclo-
nal antibody approved for patients with severe allergic 
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asthma: omalizumab, a recombinant humanized murine 
antibody against IgE antibodies. A recent study from 
our group investigated the effect of long-term anti-IgE 
treatment on the thickening of the RBM and eosino-
phil infiltration in bronchial biopsies from patients 
with severe persistent allergic asthma. Our results 
showed that a substantial proportion of severe asthmat-
ics reduced the original bronchial RBM thickness and 
eosinophil infiltration after one-year treatment with 
anti-IgE, thus emphasizing the possible role of omali-
zumab  in affecting airway remodeling in severe persis-
tent allergic asthma [31]. Up to now, many studies have 
shown how the anti-IgE treatment in SA patients was 
effective in modulating airways remodeling and inflam-
mation, as well as in improving lung functions and qual-
ity of life (Table 1).
Eosinophils count in induced sputum has long been the 
method of choice to evaluate eosinophilic lung inflam-
mation and seems to be a reliable biomarker of airway 
inflammation as well as useful in adjusting corticosteroid 
treatments in asthma [38–40].
Newby et al. and McGrath et al. by using sputum, iden-
tified phenotypes of SA enriched for eosinophilic airway 
inflammation that might respond to therapies directed 
toward Th2 immune pathways [41, 42].
Recently, the dose ranging efficacy and safety with 
mepolizumab (DREAM) study correlated blood eosino-
phils levels, but not sputum eosinophilia, with response 
to mepolizumab [43]. These data are supported by many 
authors who evidenced that sputum eosinophils can not 
predict treatment response and that increased blood 
eosinophils are associated with higher risk for exacer-
bations, maybe owing to interleukin (IL)-5 levels [44, 
45]. Following anti-IgE treatment, some studies found 
decreased blood eosinophils counts [46]. In the EXTRA 
study, Hanania and colleagues demonstrated that omali-
zumab efficacy was strongly related to the presence of 
airways eosinophilic inflammation and more accurately 
predicted by FeNO and serum periostin rather than IgE 
levels [47].
It is currently hypothesized that the use of blood eosin-
ophils  as biomarkers could help to personalize asthma 
management in patients with severe allergic asthma.
Active eosinophils recruitment is predominantly 
exerted by proteins secreted by epithelia, the most 
potent chemoattractant for these cells being eotaxin-1 
(CCL11), that account for 80  % of TGF-ß expression in 
asthma [48–50]. A recent work evaluated CCL11 levels 
in bronchoalveolar lavage fluid (BALF), exhaled breath 
condensate (EBC), blood and sputum and evidenced a 
Table 1 Studies on clinical effectiveness of omalizumab in patients with severe asthma
ET-1 endothelin-1, FeNO fractional exhaled nitric oxide, ECP eosinophil cationic protein, FEV1 forced expired volume in 1 s, EB exhaled breath, EBC exhaled breath 
condensate, RANTES/CCL5 regulated on activation, normal T cell expressed and secreted/chemokine (C–C motif ) ligand-5, PEF peak expiratory flow, CalvNO estimated 
alveolar nitric oxide concentration, CT computerized tomography, ACT asthma control test.
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correlation between this protein in induced sputum and 
asthma severity [51].
It has also been hypothesized that asthma sever-
ity might be linked to a relationship between TGF-ß 
expression and the presence of submucosal eosinophils. 
It was evidenced that in bronchial biopsies the majority 
of eosinophils is TGF-ß1-mRNA positive [25, 52], with 
a higher extent in SA. Moreover, TGF-ß2 isoforms are 
expressed by eosinophils in severe allergic asthma where 
this cytokine promotes fibrotic responses and regulates 
mucin production [53, 54].
Although still in study and source of debate, the per-
sistent eosinophilic phenotype in adults might be a real 
candidate for specific therapies thus potentially interfer-
ing with the natural history of SA with high exacerbation 
rates.
Fractional exhaled nitric oxide
Epithelial inducible nitric oxide synthase (NOS) has 
been shown to be the main determinant of FeNO lev-
els in the respiratory tract [55] due to increased nitric 
oxide (NO) production by activated bronchial epithelial 
cells in response to pro-inflammatory stimuli [56]. It is 
postulated that the decrease in FeNO values seen after 
steroid treatment might be due to an inhibitory effect 
of these drugs on inducible NOS activity [55], therefore 
the measurement of NO concentration in exhaled breath 
has been standardized for clinical use. It is a quantita-
tive, non-invasive, simple, and safe method to assess 
airway inflammation, to monitor responsiveness to ICS 
therapy in adults [57] and to predict asthma control 
status in childhood [58]. Recently, a retrospective study 
was performed on 416 asthmatic patients on combined 
therapy (long-acting β2 agonist and ICS). The authors 
assessed the correlation between FEV1 and FeNO to 
ascertain the correct use of FeNO measurement in dif-
ferent asthma phenotypes with regard to disease control, 
severity, allergy, comorbidity, obesity, age and smoking 
status. No correlation was found between FeNO lev-
els and asthma severity but it was shown a link to other 
parameters such as age, gender, history of emergency 
room visits and atopy [59]. Moreover, cross-sectional 
study on 100 adult asthmatic patients showed that FeNO 
levels were correlated primary with asthma control 
rather than asthma severity, confirming FeNO as reliable 
biomarker in asthma management [60]. Peirsman et  al. 
performed a randomized controlled trial on 99 children 
with persistent allergic asthma: patients outcomes were 
evaluated over a 52-week timeframe and, only in FeNO 
group, therapeutic approach was guided by FeNO meas-
urements. Results demonstrated that FeNO evaluation 
diminished asthma exacerbations rate in associated with 
an increased leukotriene receptor antagonist use and ICS 
doses administration [61]. FeNO may also be used as pre-
dictor of omalizumab treatment efficacy. Hanania et  al. 
evaluated FeNO, serum periostin and blood eosinophilia 
as potential biomarkers useful to evaluate effectiveness of 
anti-IgE treatment on 850 adult persistent SA patients. 
After 48 weeks of therapy, reduction of exacerbations rate 
was greater in high versus low subgroup for FeNO levels 
(53 vs 16  %) [47]. In the Inner-City Anti-IgE therapy of 
asthma trial, Busse et al. confirmed a clinical benefit from 
omalizumab treatment in children and adolescents [62]. 
In a post hoc analysis of the previous study, Sorkeness 
et al. found that FeNO, together with blood eosinophils 
and body mass index, can predict omalizumab response 
[63]. Moreover, preliminary data indicated that elevated 
FeNO may be indicative of anti-IL-13/IL-4 biological 
response [64]. However, Haldar et al. showed that FeNO 
seems to be less closely associated with a response to 
mepolizumab (anti IL-5) than blood eosinophils count 
[65].
In SA, the bronchial mucosa is markedly hyperplastic, 
the epithelium may be susceptible to destruction, flaking 
and detachment from the RBM. Therefore, FeNO lev-
els can be under-representative [66]. The ERS/ATS Task 
Force has published a detailed guideline on definition, 
evaluation and treatment of SA. The Authors defined SA 
phenotypes giving specific recommendations for the use 
of diagnostic tools like measurement of FeNO to guide 
therapy. Elevated FeNO value is considered as a marker 
of Th2 inflammation and atopy but not an effective bio-
marker useful in SA management [1].
Exhaled breath condensate
Exhaled breath (EB) is mainly composed by aerosolized, 
non-volatile particles of airway lining fluid collected 
from the airways by airflow turbulence, water vapor 
condensation, inorganic (O2, N2), and organic (CO2) 
atmospheric volatile water-soluble gases, endogenous 
and exogenous volatile organic compounds [67]. EBC 
is the EB that has been condensed, typically by using a 
commercially available refrigerating device, according 
to ATS/ERS Guidelines [68]. It is used to investigate the 
composition of airway fluids and to achieve informa-
tion about pulmonary alveoli, inflammation, nitrosative 
and oxidative stress in airways diseases such as COPD 
[69], asthma [70] and lung cancer [67]. Concerning SA, 
clinical studies identified chemical and biological char-
acteristics that distinguish EBC of severe asthmatics 
from those obtained from healthy subjects and mild to 
moderate asthmatic patients (Fig. 1). Experimental data 
on EBC pH in SA are contrasting and there are still few 
studies about it [71, 72]. Eicosanoids as pro-inflam-
matory Leukotriene B4 (LTB4) and anti-inflammatory 
Lipoxin A4 (LXA4) are increased in asthmatics versus 
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healthy subjects and LXA4/LTB4 ratio dramatically 
decreases in EBC in correlation with asthma severity 
[73]. Eotaxin-1 was evaluated in blood, EBC, sputum 
and BALF and was proposed as a tool for assessment 
of asthma severity [51]. High levels of nitrogen reac-
tive species (NO, NO2−, NO3−) and endogenous ROS 
(superoxide, hydrogen peroxide, hydroxyl radical) pro-
vided evidence for pathologic oxidizing processes in 
asthma and are indicative of airways oxidative and 
nitrosative stress [74]. In SA, these pathologic features 
are exacerbated and correlated to asthma stability and 
corticosteroid therapy response [75]. Many studies have 
been published on the use of omics techniques in asth-
matic children for the analysis of easy to be collected 
samples. Using liquid chromatography and mass spec-
trometry, significant differences useful to distinguish 
asthma severity between healthy and asthmatic children 
biochemical profiles were found in urine and in EBC 
[76–78]. Baraldi et al. proposed the use of metabolomic 
analysis or breathomic approach of EBC to character-
ize asthma phenotypes and personalize the therapeu-
tic plan [79]. Fitzpatrick et  al. found that SA children 
showed metabolic differences associated with oxidative 
stress-related pathways which may contribute to their 
corticosteroids refractory state [80]. General recom-
mendations for EBC collection and exhaled biomarkers 
measurements are available in order to avoid a possible 
alteration in biomarker concentrations. Despite EBC 
collection remains a procedure potentially influenced by 
numerous endogenous and exogenous factors, in pre-
sent and in future, EBC analysis can turn out as a prom-
ising, safe and non-invasive method for monitoring SA 
patients [68].
Periostin
Periostin is a secreted matricellular protein with a key 
role in amplification and in persistence of chronic inflam-
mation of allergic diseases [81]. Having the ability to bind 
fibronectin, tenascin-C, collagen I, III and V, periostin is 
involved in the process of subepithelial fibrosis in asthma 
patients [82]. Furthermore, it exerts its biological activ-
ity also by binding integrins on cell surfaces and activat-
ing intracellular signal pathways [83]. Periostin is induced 
by IL-4 and IL-13 in bronchial epithelial cells and in 
lung fibroblasts and its expression is correlated with the 
RBM thickness [82, 84, 85]. Moreover, this molecule is 
Fig. 1 Changes in exhaled breath condensate mediators values in severe asthma.
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able to accelerate eosinophils tissue infiltration facilitat-
ing their adhesion to extracellular matrix proteins [86]. 
Serum periostin can be considered a systemic biomarker 
Th2-high asthma related because it is a signature mole-
cule associated to higher AHR, serum IgE, eosinophilic 
inflammation, subepithelial fibrosis, compared to Th2-
low asthma. It is possible to consider serum periostin a 
promising biomarker for two main reasons. First of all, 
this protein easily moves from inflamed tissues to blood 
circulation so its serum concentrations reflects its local 
production in lesions induced by Th2-type immune 
responses [87, 88]. Moreover, its basal serum levels are 
physiologically relatively low (~50  ng/ml) compared to 
other extracellular matrix proteins such as fibronectin 
or vitronectin. Jia et  al. in the Bronchoscopic Explora-
tory Research Study of Biomarkers in Corticosteroid-
refractory Asthma (BOBCAT), identified serum periostin 
as the single best systemic biomarker of airway luminal 
and tissue eosinophilia in severe, uncontrolled asthmat-
ics. Adopting 25  ng/ml serum periostin as an arbitrary 
cut-off, eosinophil-low and eosinophil-high patients are 
effectively differentiated, with a positive predicted value 
of 93  %. This study evidenced the superiority of serum 
periostin for predicting sputum and tissue eosinophilia, 
compared to blood eosinophils, IgE levels, YKL-40 and 
FeNO [89]. More recently, Kanemitsu et al., in an obser-
vational study, found that high serum periostin concen-
tration (≥95  ng/ml) is the unique biomarker, among 
several serum markers, associated with the greater 
annual decline in FEV1 (at least 30 ml/year) [90]. In addi-
tion to being an encouraging biomarker in predicting 
responders to traditional ICS therapy, periostin seems to 
also identify responders to new target treatments [91]. 
Corren et  al. demonstrated that its higher serum levels 
might predict the response to Th2 target therapy with 
biologic agents such as anti-IL-13 monoclonal antibody 
(lebrikizumab). The Authors performed a randomized, 
double-blind, placebo-controlled study of lebrikizumab 
in 219 adults with unstable asthma despite ICS treat-
ment. The therapy was associated with increased FEV1 
values in patients with high pretreatment levels of serum 
periostin [92]. Similarly, analyzing the results from the 
EXTRA study performed with uncontrolled, severe, aller-
gic asthmatics, Hanania et al. found that the high serum 
periostin group had a greater decreased exacerbation rate 
after omalizumab treatment compared to low serum per-
iostin group [47]. Finally, in a recently published study, 
Bobolea et  al. investigated the potential role of sputum 
periostin, more organ-targeted than serum periostin, as 
a biomarker of SA. The Authors found that sputum peri-
ostin levels are associated with persistent airflow limita-
tion and eosinophilic inflammatory phenotype despite 
high-dose ICS therapy [93].
Taken together, these results show that periostin can 
be a useful biomarker to apply stratified medicine for 
SA and to yield better outcomes in asthma management. 
More evaluations are required to validate and clarify 
the potential utility of periostin in research and before 
this measurement can be applied in everyday clinical 
practice. Future studies should better evaluate this bio-
marker because it was demonstrated that its high levels 
could be detected in several conditions associated with 
increased cellular proliferation, angiogenesis, stress, tis-
sues injury not necessarily dependent on a Th2 immune 
response, as shown in Table 2. We should also remember 
that periostin is not specific to asthma or the airway epi-
thelium [81, 109, 123, 124]. These considerations should 
Table 2 Overview on  periostin as  biomarker in  different 
diseases
References
Allergic and respiratory diseases
Asthma [89]
Atopic dermatitis [94]
IgG4-related sclerosing sialadenitis [95]
Allergic rhinitis and chronic rhinosinusitis [96]
Eosinophilic otitis media [97]
Idiopathic interstitial pneumonias [98]
Pulmonary fibrosis [99]
Nasal polyps associated with aspirin-sensitive asthma [100]
Oncology
Cholangiocarcinoma [101, 102]
Ovarian carcinoma [103, 104]
Colon cancer [105]
Pancreatic cancer [106, 107]
Melanoma [108]
Head and neck cancer [109]
Glioblastoma [110]
Breast cancer [111]
Non-small cell lung carcinoma [112]
Osteology




Proliferative diabetic retinopathy [116]
Psoriasis [117]
Interstitial renal fibrosis [118]
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lead clinicians to use an integrative approach which links 
clinical features and molecular mechanisms and should 
encourage to better investigate analysis of sputum peri-
ostin. It will also be necessary to establish and validate 
cut-off values to define high and low periostin levels. 
Furthermore, additional carefully designed studies are 
needed to evaluate if periostin, alone or in combination 
with other more conventional biomarkers, can be uti-
lized in better redefining current asthma phenotypes and 
selecting patients for emerging asthma therapeutics tar-
geting Th2 inflammation.
Galectins
Galectins are a family of animal lectins with different 
cellular and extracellular localizations. These proteins 
bind the cell-surface and extracellular matrix (ECM) gly-
cans and, thereby, affect a variety of cellular processes 
and biological activities. To date, 15 galectins having a 
role in physiological and pathobiological processes like 
cancer, heart failure, tissue repair and platelets aggrega-
tion have been found in mammals [125–128]. Regard-
ing airway diseases, the effects of these proteins on the 
inflammatory process were analyzed for the first time in 
murine models. Galectin-9 role is still unclear because 
it was identified as a possible recruiter of eosinophil 
granulocytes and promoter of Th2 dominance [129], but 
also as a IgE binding protein with anti-allergic effects 
able to prevent acute asthma exacerbations [130, 131]. 
Another galectin with a demonstrated role in asthma 
is Galectin-3, the only chimera galectin found in Ver-
tebrates, with biological activities in numerous cellular 
functions like cellular adhesion, growth, chemoattrac-
tion, differentiation, apoptosis and cellular cycle as well 
as an IgE binding protein activity [132–134]. Evalua-
tion of Galectin-3 expression in deficient and wild-type 
gal-3 mice with OVA-induced asthma, evidenced that 
OVA-sensitized gal-3 (−/−) mice developed fewer 
eosinophils, lower goblet cell metaplasia and signifi-
cantly less AHR after airway OVA challenge compared 
to similarly treated gal-3 (+/+) mice [135]. Moreover, 
studies on Gal-3 gene therapy confirmed how it is pos-
sible to reduce eosinophils airway infiltration, AHR and 
tissue remodeling [136]. The involvement of Galectin-3 
in human airways inflammatory process has been ascer-
tained for COPD [137], lung fibrosis [138] and asthma. 
In asthma, Gal-3 expression seems to be related to the 
development of a specific inflammatory pattern and 
biological therapy outcome. Recently, Gao et  al. found 
a significantly reduced sputum Gal-3 in patients with 
neutrophilic asthma [139]. Moreover, evaluating bron-
chial biopsies of SA patients treated with omalizumab 
using proteomic technique, we observed that proteomic 
profile of bronchial tissue before omalizumab treatment 
presents a typical pattern indicative of anti-IgE treat-
ment response. Galectin-3 was expressed only in sub-






















Fig. 2 Possible clinical meaning of Galectin 3 in severe asthma.
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response to anti-IgE treatment. In our opinion Galec-
tin-3, having the ability to bind IgE proteins, can be con-
sidered a reliable biomarker to predict the modulation of 
airway remodeling and the improvement of pulmonary 
function in SA patients before they begin omalizumab 
therapy (Fig. 2) [37].
Conclusions
The need in finding biomarkers useful to moni-
tor treatment response is evident in clinical practice, 
however their discovery is made difficulty by the huge 
number of proteins involved in severe asthma patho-
genesis, only a part of which has been cited in this 
work. Recently, advances have been obtained by data 
analysis from genomic and proteomic profiling studies 
but the application of these methods in clinical prac-
tice is difficult. One of the main problems is the cost of 
many techniques, which require specific instrumenta-
tion and skills not easy to achieve. Moreover, protein 
concentrations may change depending on the inflam-
matory condition of the patient, disease-associated 
processes and the sample collecting/analysis method. 
Nonetheless, each of candidate biomarkers is involved 
in different biological aspects and gives us informa-
tion that can be largely overlapping. All these rea-
sons make clear that the road to the identification and 
the daily use of defined biomarkers in SA is still long 
and winding. Development of novel serum/sputum-
based biomarker panels with improved sensitivity and 
specificity over the ones currently available, will lead 
to promising future in the diagnosis of SA [140–142]. 
Accordingly with Gustafson et  al., the more suitable 
reality in clinical practice will be: a definition of differ-
ent panels composed by different biomarkers leading 
to the eligibility of the patients to a certain therapeutic 
treatment [143].
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